Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study

Am J Hematol. 2019 Apr;94(4):E90-E93. doi: 10.1002/ajh.25387. Epub 2019 Jan 8.

¹ Division of Hematologic Malignancies, Memorial Sloan Kettering Cancer Center, New York, New York.
² Department of Medicine, Weill Cornell Medical College, New York, New York.
³ Center for Blood Cancer, Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee.
⁴ Division of Oncology, Washington University, St. Louis, Missouri.
⁵ Division of Cancer Medicine, MD Anderson Cancer Center, Houston, Texas.
⁶ Biology and Pharmacology, Portola Pharmaceuticals, Inc., South San Francisco, California.
⁷ Clinical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.
⁸ Drug Metabolism and Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.
⁹ Pharmacokinetics, Portola Pharmaceuticals, Inc., South San Francisco, California.
¹⁰ Regulatory Affairs, Portola Pharmaceuticals, Inc., South San Francisco, California.
¹¹ Clinical Operations, Portola Pharmaceuticals, Inc., South San Francisco, California.
¹² Corporate Development, Portola Pharmaceuticals, Inc., South San Francisco, California.
¹³ Medicinal Chemistry and Chemical Development, Portola Pharmaceuticals, Inc., South San Francisco, California.
¹⁴ Research and Development, Portola Pharmaceuticals, Inc., South San Francisco, California.
¹⁵ Drug Development Unit, Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, Florida.

No abstract available

Publication types

4-(cyclopropylamino)-2-((4-(4-(ethylsulfonyl)piperazin-1-yl)phenyl)amino)pyrimidine-5-carboxamide
Pyrimidines
Sulfones
Janus Kinases
SYK protein, human
Syk Kinase